Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Skyunolide I compound and application thereof in treating myocardial hypertrophy disease

A technology of citrolactone and myocardial hypertrophy, which is applied in the field of medicine, can solve the problem of myocardial hypertrophy without citrolactone I, and achieve the effect of inhibiting myocardial hypertrophy

Pending Publication Date: 2022-03-22
CHIATAI QINGCHUNBAO PHARMA
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, there is no research on the treatment of myocardial hypertrophy with chuanxionglide I, and there is no research on the combination of salvianolic acid B and chuanxionglide I for the treatment of myocardial hypertrophy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Skyunolide I compound and application thereof in treating myocardial hypertrophy disease
  • Skyunolide I compound and application thereof in treating myocardial hypertrophy disease
  • Skyunolide I compound and application thereof in treating myocardial hypertrophy disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] 1. Experimental animals and reagents

[0039] Neonatal SD rats (suckling mice) (1-3 days), male or female, Shanghai Slack Experimental Animal Co., Ltd., the experimental animal license number is SCXK (Shanghai) 2017-0005. The reagents and consumables are listed in Table 1.

[0040] Table 1

[0041]

[0042]

[0043] 2. Reagent preparation method

[0044] D-Hank's balanced salt solution: NaCl: 8g, KCl: 0.4g, NaCl 2 HPO 4 12H 2 O: 0.135g, KH 2 PO 4 : 0.06g, NaHCO 3 : 0.35g, dissolved in 1000mL pure water, adjusted to pH 7.0-7.2, tied with kraft paper, sterilized under high temperature and high pressure, and stored at 4°C after cooling.

[0045] DMEM / F12 culture medium: Dissolve 10.6g DMEM / F12 powder in 1000mL 15-20℃ pure water, stir with a magnetic stirrer for 30min, add 1.18g NaHCO 3 Until it is completely dissolved, adjust the pH to 7.0-7.2, filter through a 0.22 μm microporous membrane, and store at 4°C.

[0046] Fetal bovine serum (standard): 56°C, 30m...

Embodiment 2

[0081] 1. Experimental animals and reagents are the same as in Example 1.

[0082] 2. The culture process of neonatal rat cardiomyocytes is the same as in Example 1.

[0083] 3. Grouping and administration

[0084] Cells were cultured for 48 hours and replaced with serum-free medium, starved for 12 hours, modeling and drug addition were carried out at the same time, and divided into 9 groups, that is, the normal control group (Control): the cells were not treated, serum-free medium was added, and the high-glucose and high-insulin group (Model, HGI for short): High glucose (25.5mmol / L)+high insulin (0.1μmol / L) medium, HGI+salvianolic acid B group: HGI+80μmol / L, HGI+ ligustalactone I(A) group : HGI+100μmol / L, HGI+ Ligusticolide I (B) group: HGI+50μmol / L, HGI+ Ligusticolide I (C) group: HGI+20μmol / L, Compatibility Group A (HGI+salvianolic acid B 80μmol / L+ chuanxionglide I 100μmol / L), compatibility group B (HGI+ salvianolic acid B 80μmol / L+ chuanxionglide I 50μmol / L), compatibil...

Embodiment 3

[0104] 1. Experimental animals and reagents

[0105] Healthy 8-week-old C57BL / 6 male mice, weighing 20g±5g, SPF grade. Purchased from Shanghai Slack Experimental Animal Co., Ltd., the experimental animal license number is SCXK (Shanghai) 2017-0005. After one week of adaptive feeding, the animals were randomly divided into groups and the formal experiment began. The reagents and consumables are listed in Table 7.

[0106] Table 7

[0107]

[0108]

[0109] 2. Establishment, administration and sampling of ISO-induced myocardial hypertrophy model in mice

[0110] Male C57BL / 6 mice were randomly divided into 6 groups according to body weight, namely blank control group (Control), ISO group (Model), ISO+salvianolic acid B group, ISO+salvianolic acid I group, ISO+salvianolic acid B+salvianolic acid group Chuanxionglide I (compatibility) group, ISO+captopril group (positive drug), a total of 12 rats in each group, using the gradient modeling method, subcutaneous injection o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicine, in particular to a senkyunolide I compound and application thereof to treatment of myocardial hypertrophy diseases, the compound comprises senkyunolide I and salvianolic acid B according to the mass ratio of 1-5: 4, and the compound has the advantage of being good in myocardial hypertrophy treatment effect.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to a Ligusticolide I complex and its application in the treatment of myocardial hypertrophy. Background technique [0002] Myocardial hypertrophy is a compensatory response to the increase in the volume and mass of cardiomyocytes produced by the heart to adapt to various stimuli. It often occurs in diseases such as hypertension and valvular disease, and is an independent risk factor that causes a significant increase in the incidence and mortality of cardiovascular disease. It mainly manifests as changes in the phenotype of cardiomyocytes, increased volume, changes in the type of contractile proteins in cardiomyocytes, proliferation of myocardial interstitial cells, hyperplasia of fibrous tissue, and production of a large amount of collagen and cellulose, all of which make myocardial structure disorder. Myocardial contractility and compliance are reduced, myocardial blood supply ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61K31/343A61P9/00A61P9/12A61P9/10A61P3/10A61P9/04
CPCA61K31/365A61K31/343A61P9/00A61P9/12A61P9/10A61P3/10A61P9/04A61K2300/00
Inventor 王毅赵璐赵滢周琢艳刘雳
Owner CHIATAI QINGCHUNBAO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com